Shijiazhuang Pharma Group (CSPC)   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Hong Kong China (1992)
Status: No NME R&D (1992)

Organization Overview

First Clinical Trial
2011
NCT01342042
First Marketed Drug
2005
gabapentin (neurontin)
First NDA Approval
2019
levamlodipine (Conjupri)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

39 Lianhuachi East Road, Haidian Dist., Beijing, China | Clinical Medicine Department CSPC R&D Business Division | Conjupro Biotherapeutics Inc, and CSPC | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | CSPC Megalith Biopharmaceutical Co., Ltd. | CSPC-NBP PHARM | CSPC-NBP Pharmaceutical Co., Ltd. | CSPC NBP PHARM CO | CSPC OUYI | CSPC OUYI PHARMA CO LTD | CSPC OUYI PHARM CO | CSPC Pharmaceutical Group Limited | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Department of medicine, CSPC clinical development division | Department of Medicine, CSPC Clinical Development Division | Shanghai Runshi Pharmaceutical Technology Co., Ltd.